Chemokine Therapeutics Receives Approval From Hong Kong to Commence Phase II Study in Liver Cancer
The Phase II trial will be an international, multi-centre, randomized, controlled, open label study assessing the efficacy and safety of CTCE-9908 that will include up to 132 patients with liver cancer.
"Liver cancer is more prevalent in the Asian communities and working with Dr. Ronnie Poon, Principal Investigator for Hong Kong, will help to expedite the patient recruitment process," stated Walter Korz, President and Chief Executive Officer of the Company.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.